Robert Lim

4.4k total citations · 1 hit paper
9 papers, 3.3k citations indexed

About

Robert Lim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Robert Lim has authored 9 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 2 papers in Surgery. Recurrent topics in Robert Lim's work include Colorectal Cancer Treatments and Studies (4 papers), Cystic Fibrosis Research Advances (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Robert Lim is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cystic Fibrosis Research Advances (2 papers) and Lung Cancer Treatments and Mutations (2 papers). Robert Lim collaborates with scholars based in United States, Singapore and Hungary. Robert Lim's co-authors include Eric Van Cutsem, Christopher Stroh, Tamás Pintér, G. Bodoky, Erika Hitre, J. Załuski, Geert D’Haens, Philippe Rougier, Anatoly Makhson and Claus-Henning Köhne and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Lim

8 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Robert Lim

Since Specialization

Citations

This map shows the geographic impact of Robert Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lim more than expected).

Fields of papers citing papers by Robert Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lim. The network helps show where Robert Lim may publish in the future.

Co-authorship network of co-authors of Robert Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lim. A scholar is included among the top collaborators of Robert Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lim. Robert Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Outcomes in relapsed/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: real-world interventions as benchmark for novel therapy 2025 ·SHILAP Revista de lepidopterología ·Nicole-Ann Lim, Yang Sun, Jing Yuan Tan, Robert Lim, Yeh Hong Tan, (unknown), Francesca Lim, Yeow Tee Goh, (unknown), Jianbang Chiang, (unknown), Eileen Poon, (unknown), M. Tao, Soon Thye Lim, (unknown), (unknown), Jason Yongsheng Chan	0
2	Expanding Approved Patient Populations for Rare Disease Treatment Using In Vitro Data 2021 ·Clinical Pharmacology & Therapeutics ·James L. Weaver, Wendy Wu, Paula L. Hyland, Robert Lim, Patroula Smpokou, Michael Pacanowski	4
3	Advancing Therapeutic Development for Pulmonary Morbidities Associated with Preterm Birth 2020 ·Therapeutic Innovation & Regulatory Science ·(unknown), Gerri Baer, (unknown), (unknown), Robert Lim, Elektra J. Papadopoulos, Michelle Campbell, Gregory W. Daniel, Susan McCune	2
4	Inhaled Corticosteroids and LABAs — Removal of the FDA’s Boxed Warning 2018 ·New England Journal of Medicine ·Samantha Seymour, Robert Lim, Changming Xia, (unknown), Badrul A. Chowdhury	17
5	The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial 2017 ·Annals of the American Thoracic Society ·Anthony G. Durmowicz, Robert Lim, Hobart Rogers, Curtis J. Rosebraugh, Badrul A. Chowdhury	101
6	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer breakdown → 2009 ·New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, (unknown), Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier	2902
7	Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial 2009 ·Journal of Clinical Oncology ·Claus Henning Köhne, (unknown), (unknown), Robert Lim, Tamás Pintér, G. Bodoky, Christopher Stroh, İ. Çeli̇k, P. Rougier, Eric Van Cutsem	22
8	Outcomes of Adjuvant Chemoradiotherapy After a Radical Gastrectomy and a D2 Node Dissection for Gastric Adenocarcinoma 2008 ·The Cancer Journal ·Cheng Nang Leong, Hans T. Chung, (unknown), Thomas P. Shakespeare, Rahul Mukherjee, (unknown), Jiade J. Lu, Jeremy Tey, Robert Lim, Jimmy Bok Yan So, Michael Back	23
9	Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients 2006 ·Journal of Clinical Oncology ·Hans‐Joachim Schmoll, Thomas H. Cartwright, Josep Tabernero, Marek P. Nowacki, Arié Figer, Jean A. Maroun, Timothy Price, Robert Lim, Eric Van Cutsem, (unknown), Joseph McKendrick, (unknown), (unknown), Filippo de Braud, Mark Hill, Florin Sirzén, Daniel G. Haller	206

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact